Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT02994069 | Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers | active not recruiting | Phase 2 | 80 | Susanne ArnoldOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) | active not recruiting | Phase 3 | 621 | Merus B.V.INDUSTRY | 24 | Sep 25, 2026 | clinicaltrials |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | active not recruiting | Phase 3 | 699 | Merus B.V.INDUSTRY | 28 | Sep 25, 2026 | clinicaltrials |
| NCT07757906 | Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection | active not recruiting | N/A | 220 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05814549 | A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) | active not recruiting | — | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT02314169 | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer | active not recruiting | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT02792582 | A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection | active not recruiting | Phase 2 | 160 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03965689 | Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | active not recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05913388 | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 12 | Providence Health & ServicesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05977907 | Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).(KIEO) | active not recruiting | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04216316 | Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04534205 | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1(AHEAD-MERIT) | active not recruiting | Phase 2 / Phase 3 | 358 | BioNTech SEINDUSTRY | 21 | Sep 21, 2026 | clinicaltrials |
| NCT05172258 | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05878288 | Deep sequencIng in Cutaneous Squamous CEll caRciNomas(DISCERN) | active not recruiting | Phase 2 | 11 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05863052 | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | active not recruiting | — | 72 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07147361 | Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma(PB-PD1R-SCC) | active not recruiting | — | 800 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT05043688 | Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | active not recruiting | Phase 3 | 426 | Zhigang LiOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05797246 | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) | active not recruiting | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05358938 | Exercise to Boost Response to Checkpoint Blockade Immunotherapy | active not recruiting | Early Phase 1 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06806852 | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | active not recruiting | Phase 1 | 91 | Boehringer IngelheimINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT07806617 | Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts | active not recruiting | Phase 2 | 55 | Rush University Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03493425 | Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | active not recruiting | Phase 2 | 82 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04166318 | Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study | active not recruiting | Phase 2 | 252 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04255849 | Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV | active not recruiting | Phase 3 | 700 | Weill Medical College of Cornell UniversityOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT04428671 | Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer | active not recruiting | Phase 1 | 14 | Emory UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05721755 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 3 | 290 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05799274 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors(RAD301) | active not recruiting | Phase 1 | 9 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140500 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 170 | Hoffmann-La RocheINDUSTRY | 9 | Sep 11, 2026 | clinicaltrials |
| NCT04444921 | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | active not recruiting | Phase 3 | 205 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06055868 | People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity | active not recruiting | — | 133 | University of California, San FranciscoOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06557889 | Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas(REDUCE) | active not recruiting | Phase 2 | 86 | Institut Claudius RegaudOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01142388 | Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | active not recruiting | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | active not recruiting | Phase 1 | 152 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03233711 | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | active not recruiting | Phase 3 | 344 | National Cancer Institute (NCI)NIH | 2 | Sep 10, 2026 | clinicaltrials |
| NCT04080804 | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | active not recruiting | Phase 2 | 80 | Dan ZandbergOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04590963 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer(INTERLINK-1) | active not recruiting | Phase 3 | 370 | AstraZenecaINDUSTRY | 23 | Sep 9, 2026 | clinicaltrials |
| NCT04947241 | Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC | active not recruiting | Phase 1 | 20 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05343325 | The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC | active not recruiting | Phase 2 | 25 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04391049 | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | active not recruiting | Phase 1 | 16 | NRG OncologyOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06727565 | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01(VELOCITY-HNSCC) | active not recruiting | Phase 2 | 39 | Gilead SciencesINDUSTRY | 9 | Sep 3, 2026 | clinicaltrials |
| NCT06761937 | Thermotherapy for Locally Advanced Head and Neck Cancer(TANCA-I) | active not recruiting | Phase 1 | 2 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05054439 | A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC | active not recruiting | Phase 2 | 45 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05945823 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | active not recruiting | Phase 2 | 53 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 1, 2026 | clinicaltrials |
| NCT06305247 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 36 | IpsenINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT02305654 | International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)(InPACT) | active not recruiting | Phase 3 | 200 | Institute of Cancer Research, United KingdomOTHER | 2 | Aug 31, 2026 | clinicaltrials |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 3 | 403 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT02270814 | Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma(CACTUX) | active not recruiting | Phase 2 | 74 | Washington University School of MedicineOTHER | 1 | Aug 28, 2026 | clinicaltrials |
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials